Clinical study of treatment of peri-chemotherapy nausea and vomiting of cancer patients using thalidomide
10.3760/cma.j.issn.1006-9801.2014.10.005
- VernacularTitle:沙利度胺改善恶性肿瘤患者围化疗期恶心、呕吐的临床研究
- Author:
Zhengxiang HAN
;
Xuan SUN
;
Jie XU
;
Yan LI
;
Xiuping DU
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Thalidomide;
Peri-chemotherapy;
Nausea;
Vomiting
- From:
Cancer Research and Clinic
2014;26(10):667-669
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the therapeutic effects and adverse reactions of thalidomide in the treatment of peri-chemotherapy nausea and vomiting of cancer patients.Methods Total of 70 patients were randomly divided into two groups:the treatment group (38 cases) and the control group (32 cases).The treatment group was treated with thalidomide (oral administration at a dose of 100 mg per night,then dose can be added by 50 mg until the top dose of 200 mg per day).The original will be maintained if they cannot be tolerate of extensive dose.The treatment group was also injected 2mg tropisetron in 30 minutes before chemotherapy.The control group was only injected same dose tropisetron.All cases were examined antiemetic effects and evaluated adverse reactions.Results Nausea and vomiting control rates were 89.5 ％ (34/38) and 68.8 ％ (22/32) respectively in the treatment group and control group respectively with significant difference.The adverse reactions were similar between the two groups.Conclusion Thalidomide joint tropisetron can effectively control the peri-chemotherapy nausea and vomiting,and the adverse reactions can be acceptable.It could improve further indications of the drug.
